Arpida AG remains on track to file for marketing approval for the intravenous antibiotic iclaprim in the U.S. and Europe before the year-end, following positive topline data from a second pivotal trial of the compound in patients with complicated skin and skin structure infection (cSSSI). (BioWorld International) Read More
